Background: Anthracyclines are essential in pediatric cancer treatment, but patients are at risk cancer therapy-related cardiac dysfunction (CTRCD). Standardized definitions by the International Cardio-Oncology Society (IC-OS) aim to enhance precision in risk assessment.
Objectives: Categorize distinct phenotypes among pediatric patients undergoing anthracycline chemotherapy using unsupervised machine learning.
Methods: Pediatric cancer patients undergoing anthracycline chemotherapy at our institution were retrospectively included. Clinical and echocardiographic data at baseline, along with follow-up data, were collected from patient records. Unsupervised machine learning was performed, involving dimensionality reduction using principal component analysis and K-means clustering to identify different phenotypic clusters. Identified phenogroups were analyzed for associations with CTRCD, defined following contemporary IC-OS definitions, and hypertensive response.
Results: A total of 187 patients (63.1% male, median age 15.5 years [10.4-18.7]) were included and received anthracycline chemotherapy with a median treatment duration of 0.66 years [0.35-1.92]. Median follow-up duration was 2.78 years [1.31-4.21]. Four phenogroups were identified with following distribution: Cluster 0 (32.6%, n = 61), Cluster 1 (13.9%, n = 26), Cluster 2 (24.6%, n = 46), and Cluster 3 (28.9%, n = 54). Cluster 0 showed the highest risk of moderate CTRCD (HR: 3.10 [95% CI: 1.18-8.16], P = 0.022) compared to other clusters. Cluster 3 demonstrated a protective effect against hypertensive response (HR: 0.30 [95% CI: 0.13- 0.67], P = 0.003) after excluding baseline hypertensive patients. Longitudinal assessments revealed differences in global longitudinal strain and systolic blood pressure among phenogroups.
Conclusions: Unsupervised machine learning identified distinct phenogroups among pediatric cancer patients undergoing anthracycline chemotherapy, offering potential for personalized risk assessment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514752 | PMC |
| http://dx.doi.org/10.1186/s40959-024-00276-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unsupervised self-organising map classification of Raman spectra from prostate cell lines uncovers substratified prostate cancer disease states.
Sci Rep
January 2025
School of Physics, Engineering and Technology, University of York, Heslington, York, YO10 5DD, UK.
Prostate cancer is a disease which poses an interesting clinical question: Should it be treated? Only a small subset of prostate cancers are aggressive and require removal and treatment to prevent metastatic spread. However, conventional diagnostics remain challenged to risk-stratify such patients; hence, new methods of approach to biomolecularly sub-classify the disease are needed. Here we use an unsupervised self-organising map approach to analyse live-cell Raman spectroscopy data obtained from prostate cell-lines; our aim is to exemplify this method to sub-stratify, at the single-cell-level, the cancer disease state using high-dimensional datasets with minimal preprocessing.
View Article and Find Full Text PDFOpen challenges and opportunities in federated foundation models towards biomedical healthcare.
BioData Min
January 2025
School of Computer Science, Fudan University, Shanghai, China.
This survey explores the transformative impact of foundation models (FMs) in artificial intelligence, focusing on their integration with federated learning (FL) in biomedical research. Foundation models such as ChatGPT, LLaMa, and CLIP, which are trained on vast datasets through methods including unsupervised pretraining, self-supervised learning, instructed fine-tuning, and reinforcement learning from human feedback, represent significant advancements in machine learning. These models, with their ability to generate coherent text and realistic images, are crucial for biomedical applications that require processing diverse data forms such as clinical reports, diagnostic images, and multimodal patient interactions.
View Article and Find Full Text PDFIntroduction to Artificial Intelligence (AI) and Machine Learning (ML) in Pathology & Medicine: Generative & Non-Generative AI Basics.
Mod Pathol
January 2025
Department of Pathology, University of Pittsburgh Medical Center, PA, USA; Computational Pathology and AI Center of Excellence (CPACE), University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address:
This manuscript serves as an introduction to a comprehensive seven-part review article series on artificial intelligence (AI) and machine learning (ML) and their current and future influence within pathology and medicine. This introductory review provides a comprehensive grasp of this fast-expanding realm and its potential to transform medical diagnosis, workflow, research, and education. Fundamental terminology employed in AI-ML is covered using an extensive dictionary.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: Frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) constitute a clinicopathologic spectrum with multifaceted heterogeneities. Brain transcriptomics may help to identify molecular subtypes of FTD and/or ALS but this testing is only possible at autopsy and thus is cross-sectional and representative of end-stage disease. Subtype and Stage Inference (SuStaIn) is an unsupervised machine-learning algorithm that was employed to identify temporal dynamics of data-driven subtypes of ALS and FTD.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Kansas Medical Center, Kansas City, KS, USA.
Background: The medical and social history of patients with Alzheimer's Disease is heterogeneous with many interacting genetic and environmental factors contributing to an individual's risk. Moreover, a maternal family history (mFH) is a key risk factor for AD-raising the risk for disease onset by as much as nine times. However, a proportion of individuals do not have a complete knowledge of their family history.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!